Healthcare >> Analyst Interviews >> November 21, 2011
Duane Nash, M.D., is a Senior Vice President in the equity research department of Wedbush Securities, which he joined in 2009 upon Wedbush's acquisition of Pacific Growth Equities, LLC. Before joining the sell side, Dr. Nash was employed with the law firm of Davis Polk & Wardwell LLP, where he practiced intellectual property litigation, as well as patent evaluation and strategy in the merger-and-acquisition context. Previously, Dr. Nash worked at two other Bay Area law firms, and also completed his internship in general surgery at the University of California, San Francisco. He received his B.A. in biology from Williams College, his M.D. from Dartmouth Medical School, his J.D. from the University of California, Berkeley, and his MBA from the University of Oxford. Dr. Nash is a California-licensed physician and also a Member of the The State Bar of California. Profile
TWST: What is your coverage in the pharma sector?
Dr. Nash: I cover drugs and devices in the heart and liver space. For example, I tend to cover in the liver space companies that are primarily focused